AI video generation is becoming a table-stakes feature for modern digital platforms. The developers who integrate it now are ...

What is the concept behind GCDS Spring 2026? The collection celebrates the brand’s 10th anniversary by revisiting its most ...

Choosing between SAML, OIDC, and OAuth 2.0? Explore 12 critical differences to help your B2B engineering team select the right authentication protocol today.

The mining project of MCC Jiangxi Copper Aynak Mining Co., Ltd. in Afghanistan is of strategic and economic importance. However, the region’s long-term conflict has disrupted the local talent ...

By Thomas Rogers The 22-year-old Swiss writer Nelio Biedermann has strange memories of visiting his family’s old properties when he was a child. Although he grew up middle-class in Zurich, his father ...

The Dallas Cowboys still have multiple positions to address ahead of the 2026 NFL season, with edge rusher being at or near the top of the list. While the addition of Rashan Gary via trade with the ...

India’s transition toward piped natural gas (PNG) for domestic cooking is gathering pace, with regulators and city gas distribution companies tightening rules to streamline household gas supply. Under ...

The Cavaliers suffer multiple injuries entering the late stages of the regular season. Will these injuries haunt them yet again? Matt Palange dives into it Millions protest Trump administration at "No ...

SISQUOC, Calif. (KEYT) - The Santa Barbara County Board Of Supervisors adopted a new ‘Environmental Justice Element’ to its Comprehensive Plan at Tuesday’s meeting. It’s a state mandate that gives ...

The Indianapolis Colts have agreed to a two-year deal with former Titans defensive end Arden Key. The veteran defensive end recorded 16.5 sacks over the past three seasons in Tennessee. Key is ...

The Colts have moved on to the defensive side of the pall after making a pair of wide receiver moves on Monday. According to multiple reports, they have agreed to a two-year deal with edge rusher ...

Roche Holding said a drug candidate for multiple sclerosis met the primary goal in a late-stage clinical trial for the most common form of the disease. The Swiss pharmaceutical company said Monday ...